Facebook-f Linkedin-in

Asian listed biotech with mid-stage oncology data requiring a transaction

Tags

Korea
Publicly listed
Oncology
Clinical Stage

Overview

An Asian listed biotech had a phase 2 oncology asset in development for combination therapy.

The asset was undergoing clinical investigation in various combinations in collaboration with different multinational corporations.

Situation and Challenges

  • Combination studies were undertaken with a significant number of multinational corporations.
  • The studies had generated a significant amount of promising data across the various data sets.
  • However, the data generation had not resulted in a transaction, forcing the company to continue development of the asset into later stages.

Treehill Solution

Treehill employed a principal’s mentality:

Determined focus indications for the entire pipeline.

Further enhanced the commercial value of these new focus indications.

Developed a strategy for engaging with various types of counterparties in parallel to maximize optionality and ultimately asset value.

Supported equity story creation and capital raise for more commercially versatile clinical development.

Conclusion and Outcome

Fresh discussions with a range of multinational corporations in parallel to commercially-relevant clinical development.